Case Report
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 28, 2020; 26(16): 1971-1978
Published online Apr 28, 2020. doi: 10.3748/wjg.v26.i16.1971
Severe steroid refractory gastritis induced by Nivolumab: A case report
Helene Hjorth Vindum, Jørgen S Agnholt, Anders Winther Moelby Nielsen, Mette Bak Nielsen, Henrik Schmidt
Helene Hjorth Vindum, Anders Winther Moelby Nielsen, Henrik Schmidt, Department of Oncology, Aarhus University Hospital, Aarhus 8200, Denmark
Jørgen S Agnholt, Department of Gastroenterology, Aarhus University Hospital, Aarhus 8200, Denmark
Mette Bak Nielsen, Department of Pathology, Aarhus University Hospital, Aarhus 8200, Denmark
Author contributions: Schmidt H and Agnholt JS diagnosed and treated the patient; Vindum HH and Nielsen AWM did the literature research and manuscript preparations; Nielsen MB did the pathologic analysis, and Vindum HH drafted the manuscript; Schmidt H, Agnholt JS, and Nielsen MB contributed to manuscript drafting and revision; All authors issued final approval for the submitted version.
Informed consent statement: Informed consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Helene Hjorth Vindum, MD, Senior Registar, Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus 8200, Denmark.
Received: February 7, 2020
Peer-review started: February 7, 2020
First decision: February 27, 2020
Revised: March 5, 2020
Accepted: April 18, 2020
Article in press: April 18, 2020
Published online: April 28, 2020
Core Tip

Core tip: Lower gastrointestinal side effects, such as diarrhea and colitis, caused by immune checkpoint inhibitors are well described, but upper gastrointestinal side effects are less frequently reported. Here, we present a case of severe corticosteroid refractory gastritis induced by Nivolumab. The patient’s symptoms resolved after administration of Infliximab. The treatment was in line with current guidelines for treatment of gastritis.